ReviewFrontiers in immunology2026
Advances in immunotherapy for HPV-associated malignancies: emerging strategies and clinical progress.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomavirus (HPV) is the principal etiological factor in the majority of cervical, oropharyngeal, anal, and vulvar cancers. Persistent infection with high-risk HPV types promotes immune evasion, malignant transformation, and tumor progression. Currently licensed prophylactic HPV vaccines, based on L1 virus-like particles, are highly effective at preventing new infections and HPV-associated neoplastic disease through the induction of neutralizing antibodies. However, they do not eradicate established infections or preexisting lesions. These limitations have driven the development of therapeutic HPV vaccines and adoptive T-cell strategies aimed at eliciting robust cell-mediated immunity against HPV-associated malignancies. The viral oncoproteins E6 and E7 are attractive therapeutic targets. They disrupt cell-cycle control and are consistently expressed in HPV-driven precancerous and cancerous lesions. In this review, we provide a comprehensive overview of therapeutic HPV vaccines-including viral and bacterial vectors, DNA and RNA constructs, peptide/protein vaccines, and cell-based approaches-all designed to target E6 and E7, while considering the benefits and limitations of each platform. We also present an in-depth analysis of adoptive T-cell therapies, highlighting Immuno-STAT, a peptide-HLA fusion platform for the direct expansion of HPV-specific CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.